Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Palantir Technologies raises its full-year outlook but the stock falls, Ford suspends guidance because of uncertainty over ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.

Hims & Hers reported strong financial results for the first quarter of 2025, with revenue rising 111% year-over-year to $586.0 million. Net income for the quarter was $49.5 million, up from $11.1 ...

Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.